MX2023012324A - Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes. - Google Patents

Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes.

Info

Publication number
MX2023012324A
MX2023012324A MX2023012324A MX2023012324A MX2023012324A MX 2023012324 A MX2023012324 A MX 2023012324A MX 2023012324 A MX2023012324 A MX 2023012324A MX 2023012324 A MX2023012324 A MX 2023012324A MX 2023012324 A MX2023012324 A MX 2023012324A
Authority
MX
Mexico
Prior art keywords
specific
charge distribution
igg molecule
chain pairing
electrostatic steering
Prior art date
Application number
MX2023012324A
Other languages
English (en)
Spanish (es)
Inventor
Zhulun Wang
Bram Estes
Fernando Garces
Danyang Gong
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2023012324A publication Critical patent/MX2023012324A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023012324A 2021-04-20 2022-04-19 Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes. MX2023012324A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163177325P 2021-04-20 2021-04-20
PCT/US2022/025340 WO2022225921A1 (en) 2021-04-20 2022-04-19 Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly

Publications (1)

Publication Number Publication Date
MX2023012324A true MX2023012324A (es) 2023-10-30

Family

ID=81580206

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012324A MX2023012324A (es) 2021-04-20 2022-04-19 Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes.

Country Status (8)

Country Link
US (1) US20240182600A1 (https=)
EP (1) EP4326761A1 (https=)
JP (1) JP2024515301A (https=)
CN (1) CN117651714A (https=)
AU (1) AU2022263406A1 (https=)
CA (1) CA3216559A1 (https=)
MX (1) MX2023012324A (https=)
WO (1) WO2022225921A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202544047A (zh) * 2023-12-21 2025-11-16 美商安進公司 穩定雙細胞異二聚體產生的同源二聚體突變

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0590076A4 (en) 1991-06-14 1997-02-12 Dnx Corp Production of human hemoglobin in transgenic pigs
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
RU2009137582A (ru) 2007-03-12 2011-04-20 Эсбатек Аг (Ch) Инженерия и оптимизация одноцепочечных антител на основе последовательности
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
BRPI0813645A2 (pt) 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
RS60499B1 (sr) * 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
AR108377A1 (es) * 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
CN109475627B (zh) * 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 抗体混合物
US20220363770A1 (en) * 2019-06-28 2022-11-17 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins

Also Published As

Publication number Publication date
EP4326761A1 (en) 2024-02-28
JP2024515301A (ja) 2024-04-08
CN117651714A (zh) 2024-03-05
CA3216559A1 (en) 2022-10-27
US20240182600A1 (en) 2024-06-06
WO2022225921A1 (en) 2022-10-27
AU2022263406A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
Li et al. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics
Yu et al. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
EA201990781A1 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
Bühler et al. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells
MY205758A (en) Anti-nkg2a antibodies and uses thereof
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
EA201691925A1 (ru) Биспецифические антитела, которые связываются с cd38 и cd3
JP2016521692A5 (https=)
PE20221262A1 (es) Anticuerpos terapeuticos y sus usos
RU2018139811A (ru) Мультиспецифические антигенсвязывающие конструкции, нацеливающие иммунотерапевтические средства
HRP20200272T1 (hr) Kombinirana terapija za imunocitokine varijante il-2 usmjerene na tumor i protutijela protiv humanog pd-l1
PH12022553167A1 (en) Agonistic cd28 antigen binding molecules targeting her2
AR106570A1 (es) Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos
EA201890805A1 (ru) Биспецифические антитела против cd3*cd19
EA201300470A1 (ru) Антитела
MX2023008887A (es) Combinaciones farmaceuticas que comprenden un anticuerpo anti-ly75.
JOP20190246A1 (ar) جسم مضاد أحادي النسيلة لـ pd-l1
ZA202401043B (en) Antigen-binding polypeptide targeting b7h3 and application thereof
RU2015119159A (ru) Антитела к интерлейкину 6 и их применение
MX2023012324A (es) Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes.
Moradi-Kalbolandi et al. Evaluation the potential of recombinant anti-CD3 nanobody on immunomodulatory function
WO2020257789A3 (en) Anti-tim-3 antibodies
EA202090864A1 (ru) Моноклональное антитело к il-5r
EA202191173A1 (ru) Моноклональное антитело, которое специфически связывается с cd20
Fei et al. IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma